TY - JOUR
T1 - Salvage radiotherapy for primary refractory and relapsed diffuse large B-Cell lymphoma
AU - Brooks, Eric D.
AU - Fang, Penny
AU - Pinnix, Chelsea C.
N1 - Funding Information:
This study was supported in part by Cancer Center Core (Support) Grant CA016672 from the National Cancer Institute, National Institutes of Health, to The University of Texas MD Anderson Cancer Center.
Publisher Copyright:
© 2021 The Authors. Published by the British Institute of Radiology
PY - 2021
Y1 - 2021
N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for 30–40% of all non-Hodgkin lymphoma cases and presenting later in life, most often in the sixth decade. Although DLBCL is curable, long-term remission rates are only 60–80%. The most recent major advance in upfront therapy for DLBCL was the monoclonal anti-CD20 antibody rituximab, which was approved in the late 1990s; now, 25 years later, up to 40% of patients will experience primary refractory or relapsed disease, thereby underscoring the importance of salvage therapy. Radiation therapy can be highly effective in DLBCL, both initially as consolidation therapy and later as salvage therapy and is currently being explored in the context of immune and cellular therapies. The aim of this review is to examine the therapeutic approaches for relapsed or refractory DLBCL, with a focus on whether using radiation therapy as salvage therapy can improve the likelihood of cure.
AB - Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for 30–40% of all non-Hodgkin lymphoma cases and presenting later in life, most often in the sixth decade. Although DLBCL is curable, long-term remission rates are only 60–80%. The most recent major advance in upfront therapy for DLBCL was the monoclonal anti-CD20 antibody rituximab, which was approved in the late 1990s; now, 25 years later, up to 40% of patients will experience primary refractory or relapsed disease, thereby underscoring the importance of salvage therapy. Radiation therapy can be highly effective in DLBCL, both initially as consolidation therapy and later as salvage therapy and is currently being explored in the context of immune and cellular therapies. The aim of this review is to examine the therapeutic approaches for relapsed or refractory DLBCL, with a focus on whether using radiation therapy as salvage therapy can improve the likelihood of cure.
UR - http://www.scopus.com/inward/record.url?scp=85118202810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118202810&partnerID=8YFLogxK
U2 - 10.1259/bjr.20210360
DO - 10.1259/bjr.20210360
M3 - Article
C2 - 34378402
AN - SCOPUS:85118202810
SN - 0007-1285
VL - 94
JO - British Journal of Radiology
JF - British Journal of Radiology
IS - 1127
M1 - 20210360
ER -